Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer

Fig. 3

Linsitinib-mediated reciprocal co-activation of IGF-1R and Src confers linsitinib resistance. (a, b, c, e, and f) A549 and H1975 cells were treated with linsitinib (Linsi) (2 μM) alone (a) or in combination with dasatinib (Dasa) (100 nM) (b) for the indicated hours (a) or for 1 day (b) in the presence of 10 % FBS. H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days (c, f) or 5 days (e) either alone or in combination with dasatinib (100 nM) for the last 1 day (e). Cells treated with linsitinib for 5 days were subjected to cycloheximide treatment for the indicated time points (f). The indicated protein expression was determined by Western blot analysis. *P < 0.05. (d) in vitro kinase assay was performed using Src and IGF-1R immunoprecipitates and GST-IGF-1R or GST-Src recombinant proteins as substrates

Back to article page